Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26119473
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Prognostic role of copeptin after stroke: A systematic review and meta-analysis
of observational studies
#MMPMID26119473
Choi KS
; Kim HJ
; Chun HJ
; Kim JM
; Yi HJ
; Cheong JH
; Kim CH
; Oh SJ
; Ko Y
; Kim YS
; Bak KH
; Ryu JI
; Kim W
; Lim T
; Ahn HS
; Ahn IM
; Lee SH
Sci Rep
2015[Jun]; 5
(?): 11665
PMID26119473
show ga
Copeptin, the C-terminal part of provasopressin, has emerged as a novel
prognostic marker after hemorrhagic or ischemic stroke. The aim of this study was
to quantitatively assess the prognostic significance of plasma copeptin level on
functional outcome and mortality in patients with acute stroke using a
meta-analysis of the available evidence. Thirteen relevant studies from 2,746
patients were finally included in our study. An elevated plasma copeptin level
was associated with an increased risk of unfavorable outcome and mortality after
stroke (OR 1.77; 95% CI, 1.44-2.19 and OR 3.90; 95% CI 3.07-4.95, respectively).
The result of the pooled measure on standardized mean difference (SMD) was that
plasma copeptin levels were found to be significantly higher in patients who died
compared to survivors (SMD 1.70; 95% CI, 1.36-2.03). A stratified analysis by
study region showed significant differences in SMD of copeptin, and the
heterogeneity among studies was significantly decreased. However, the positive
association of copeptin with poor prognosis after stroke was consistent in each
stratified analysis. The present meta-analysis suggests that early measurement of
plasma copeptin could provide better prognostic information about functional
outcome and mortality in patients with acute stroke.
free
free
free
